vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $12.1M, roughly 1.2× TRANSCONTINENTAL REALTY INVESTORS INC). On growth, TRANSCONTINENTAL REALTY INVESTORS INC posted the faster year-over-year revenue change (2.3% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 0.7%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.

IRIX vs TCI — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.2× larger
IRIX
$14.7M
$12.1M
TCI
Growing faster (revenue YoY)
TCI
TCI
+72.0% gap
TCI
2.3%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
0.7%
TCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
TCI
TCI
Revenue
$14.7M
$12.1M
Net Profit
$8.3M
Gross Margin
37.2%
Operating Margin
-28.9%
Net Margin
68.8%
Revenue YoY
-69.7%
2.3%
Net Profit YoY
7577.8%
EPS (diluted)
$0.97

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
TCI
TCI
Q4 25
$14.7M
$12.1M
Q3 25
$12.5M
$12.8M
Q2 25
$13.6M
$12.2M
Q1 25
$11.9M
$12.0M
Q4 24
$12.7M
$11.8M
Q3 24
$11.6M
$11.6M
Q2 24
$12.6M
$11.8M
Q1 24
$11.8M
$11.9M
Net Profit
IRIX
IRIX
TCI
TCI
Q4 25
$8.3M
Q3 25
$-1.6M
$724.0K
Q2 25
$-994.0K
$169.0K
Q1 25
$-1.7M
$4.6M
Q4 24
$-834.0K
$108.0K
Q3 24
$-1.9M
$1.7M
Q2 24
$-2.7M
$1.5M
Q1 24
$-3.5M
$2.5M
Gross Margin
IRIX
IRIX
TCI
TCI
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
TCI
TCI
Q4 25
-28.9%
Q3 25
-11.3%
-10.9%
Q2 25
-6.9%
-6.8%
Q1 25
-1.7%
-5.3%
Q4 24
-3.9%
-14.3%
Q3 24
-16.1%
-14.4%
Q2 24
-20.9%
-9.2%
Q1 24
-28.0%
-11.2%
Net Margin
IRIX
IRIX
TCI
TCI
Q4 25
68.8%
Q3 25
-12.6%
5.6%
Q2 25
-7.3%
1.4%
Q1 25
-14.2%
38.5%
Q4 24
-6.6%
0.9%
Q3 24
-16.7%
14.7%
Q2 24
-21.2%
12.7%
Q1 24
-29.5%
21.4%
EPS (diluted)
IRIX
IRIX
TCI
TCI
Q4 25
$0.97
Q3 25
$-0.09
$0.08
Q2 25
$-0.06
$0.02
Q1 25
$-0.10
$0.53
Q4 24
$-0.05
$0.01
Q3 24
$-0.12
$0.20
Q2 24
$-0.16
$0.17
Q1 24
$-0.21
$0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
TCI
TCI
Cash + ST InvestmentsLiquidity on hand
$6.0M
$89.0M
Total DebtLower is stronger
$210.8M
Stockholders' EquityBook value
$846.7M
Total Assets
$29.2M
$1.1B
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
TCI
TCI
Q4 25
$6.0M
$89.0M
Q3 25
$5.6M
$82.7M
Q2 25
$6.8M
$73.5M
Q1 25
$7.2M
$88.6M
Q4 24
$2.4M
$99.7M
Q3 24
$3.9M
$131.6M
Q2 24
$4.1M
$127.5M
Q1 24
$5.4M
$130.8M
Total Debt
IRIX
IRIX
TCI
TCI
Q4 25
$210.8M
Q3 25
$223.5M
Q2 25
$212.4M
Q1 25
$198.2M
Q4 24
$1.0M
$181.9M
Q3 24
$1.4M
$180.3M
Q2 24
$177.4M
Q1 24
$178.3M
Stockholders' Equity
IRIX
IRIX
TCI
TCI
Q4 25
$846.7M
Q3 25
$4.7M
$838.4M
Q2 25
$6.1M
$837.7M
Q1 25
$852.0K
$837.3M
Q4 24
$2.1M
$832.3M
Q3 24
$2.6M
$832.2M
Q2 24
$4.2M
$830.4M
Q1 24
$6.5M
$828.9M
Total Assets
IRIX
IRIX
TCI
TCI
Q4 25
$29.2M
$1.1B
Q3 25
$28.4M
$1.1B
Q2 25
$31.6M
$1.1B
Q1 25
$34.2M
$1.1B
Q4 24
$29.1M
$1.1B
Q3 24
$30.2M
$1.1B
Q2 24
$31.2M
$1.0B
Q1 24
$34.1M
$1.0B
Debt / Equity
IRIX
IRIX
TCI
TCI
Q4 25
0.25×
Q3 25
0.27×
Q2 25
0.25×
Q1 25
0.24×
Q4 24
0.48×
0.22×
Q3 24
0.53×
0.22×
Q2 24
0.21×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
TCI
TCI
Operating Cash FlowLast quarter
$-2.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.35×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
TCI
TCI
Q4 25
$-2.9M
Q3 25
$-1.2M
$8.2M
Q2 25
$-397.0K
$-2.9M
Q1 25
$-1.1M
$-7.4M
Q4 24
$-1.2M
$1.3M
Q3 24
$-3.1M
$13.7M
Q2 24
$-1.3M
$-511.0K
Q1 24
$-1.6M
$3.9M
Free Cash Flow
IRIX
IRIX
TCI
TCI
Q4 25
Q3 25
$-1.2M
Q2 25
$-410.0K
Q1 25
$-1.2M
Q4 24
$-1.2M
Q3 24
$-3.1M
Q2 24
Q1 24
$-1.7M
FCF Margin
IRIX
IRIX
TCI
TCI
Q4 25
Q3 25
-9.4%
Q2 25
-3.0%
Q1 25
-9.8%
Q4 24
-9.8%
Q3 24
-26.5%
Q2 24
Q1 24
-14.0%
Capex Intensity
IRIX
IRIX
TCI
TCI
Q4 25
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
IRIX
IRIX
TCI
TCI
Q4 25
-0.35×
Q3 25
11.28×
Q2 25
-17.24×
Q1 25
-1.61×
Q4 24
12.13×
Q3 24
8.03×
Q2 24
-0.34×
Q1 24
1.52×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons